anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Burning mouth syndrome (BMS) is an intractable chronic pain disorder characterized by a burning sensation without organic abnormalities in the oral mucosa. Amitriptyline may be effective for BMS or, conversely, may exacerbate pain. QTc is necessary for monitoring psychotropic adverse effects, but it is not known if it is a predictor of efficacy for BMS. We investigated the efficacy of amitriptyline in BMS and its effect on QTc.
METHODS: Visual analog scale and electrocardiogram were examined before and 1 month after treatment in 51 consecutive patients diagnosed with BMS according to the International Classification of Headache Disorders, Third Edition (ICHD-3), criteria and treated with amitriptyline.
RESULTS: There were 26 amitriptyline responders and 25 nonresponders, with no differences in age, sex, and amitriptyline dosage. Amitriptyline responders showed little change in QTc, whereas nonresponders showed a trend toward significantly shorter QTc. Changes in visual analog scale correlated statistically significantly with changes in QTc (Spearman rank correlation coefficient: 0384; P = 0.0054). The degree of pain tended to worsen with QTc shortening.
CONCLUSION: Amitriptyline provides analgesia in about half of BMS patients, but some BMS patients have worse pain with amitriptyline. Not only do changes in the QTc detect amitriptyline adverse effects with prolongation, but also, conversely, its shortening predicts amitriptyline ineffectiveness.
Mortality at the national paediatric ward in Guinea-Bissau is very high. During a civil war in 1998/1999 the hospital case fatality (CF) decreased by more than 40%, increasing again after the the war. This was attributed to the available free drugs from the humanitarian aid and food incentives to the personnel. Free emergency kits for treatment of severe malaria was introduced, however the CF did not decline. Therefore, the ward was split into two groups of rooms: intervention and control. All the staff of the ward was trained in the use of a standardised guideline for treatment of severe malaria and randomly assigned to one of the groups. All children hospitalised for malaria received the drug emergency kits. The only difference in the intervention group were the small financial incentives and supervision for strict adherence to the guidelines procedures.
The invention discloses a pillow for treating insomnia. The pillow is characterized by comprising flexible material filling layers, a pillow interior filling layer, a zipper and a pillow interior. The pillow is divided into three layers, the upper and lower layers are the flexible material filling layers, and the middle layer is the pillow interior filling layer. The zipper is arranged on the side face of the pillow interior filling layer. The pillow interior is placed on the pillow interior filling layer. The flexible material filling layers are filled with flexible materials, and a pillow filler which comprises potentilla chinensis flower buds, parnassia palustris stems and cynanchum auriculatum fruits is arranged in the pillow interior. All insomniacs trying the pillow out have a sleep of 7 h and do not have the situation that the insomniacs wake up and cannot fall asleep again, the pain of insomnia is effectively solved, the manufacturing technology is simple, and the plant raw materials are harmless to the human body.
Participants randomly assigned to this group will receive a first cycle of SHAM multifocal tDCS (8 sessions, twice a week) and a second cycle of REAL multifocal tDCS (8 sessions, twice a week). During both cycles participant will receive cognitive stimulation treatment after brain simulation.
AIM: Prolonged postoperative ileus (PPOI) is common and is associated with a significant healthcare burden. Previous studies have attempted to predict PPOI clinically using risk prediction algorithms. The aim of this work was to systematically review and compare risk prediction algorithms for PPOI following colorectal surgery.
METHOD: A systematic literature search was conducted using MEDLINE, Embase, Web of Science and CINAHL Plus. Studies that developed and/or validated a risk prediction algorithm for PPOI in adults following colorectal surgery were included. Data were collected on study design, population and operative characteristics, the definition of PPOI used and risk prediction algorithm design and performance. Quality appraisal was assessed using the PROBAST tool.
RESULTS: Eleven studies with 87 549 participants were included in our review. Most were retrospective, single-centre analyses (6/11, 55%) and rates of PPOI varied from 10% to 28%. The most commonly used variables were sex (8/11, 73%), age (6/11, 55%) and surgical approach (5/11, 45%). Area under the curve ranged from 0.68-0.78, and only three models were validated. However, there was significant variation in the definition of PPOI used. No study reported sensitivity, specificity or positive/negative predictive values.
CONCLUSION: Currently available risk prediction algorithms for PPOI appear to discriminate moderately well, although there is a lack of validation data. Future studies should aim to use a standardized definition of PPOI, comprehensively report model performance and validate their findings using internal and external methodologies.
In 2003 Wollensak et al used corneal cross-linking (CXL) in humans to halt the progression of keratoconus. During the procedure the top layer of the cornea, the epithelium, is debrided. Then the cornea is soaked with riboflavin, a photosensitizer. Hereafter a 9.0 mm diameter Ultraviolet-A (UVA) beam radiates the cornea for 30 minutes with a fluence of 3 mW/cm2 resulting in a total energy of 5,4 J/cm2. This protocol is called the Dresden protocol. Currently, accelerated versions of the Dresden protocol are used in common practice. There are different accelerated protocols with fluences of 9mW/cm2, 10mW/cm2 and 15 mW/cm2. The higher the fluence, the shorter the treatment time, however according to the Bunsen-Roscoe reciprocity law the total amount of energy stays the same.During the procedure oxygen radicals are formed that interact with the surrounding molecules, leading to the formation of new chemical bounds between the collagen fibrils (i.e. corneal crosslinks). The final goal of the procedure is to cause the cornea to stiffen and achieve flattening of the treated region.

For any treatment, it is imperative that the unaffected region of the tissue is not unnecessarily treated by an intervention or drug application. To minimalize the risk of damage to surrounding tissues it would be beneficial that the UVA beam is restricted to the affected, keratoconic zone in the patient's cornea. This can be achieved by customizing the beam shape and size in a way that only the degenerated zone is treated, i.e. by customized cross-linking (cCXL). Recently published studies provide clinical evidence that similar clinical outcomes (amount of corneal flattening) can be achieved when only the cone is treated instead of the entire cornea.They also show the potential benefits of cCXL, e.g. the treatment is patient-specific, a smaller surface of the cornea is irradiated, lower incidence of corneal haze, a faster reepithelialisation and a shorter procedure time. However, none of these studies are randomized and study results are limited by using small sample sizes. Therefore, we feel that there is a great need for a randomized controlled trial with an appropriate design and sample size to confirm these findings.

The aim of this study is to investigate if cCXL is non-inferior to sCXL (10 mW/cm2) in terms of flattening of the corneal surface and halting the disease progression.
This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
A single-center, randomized, controlled, intra-individual comparison, evaluator-blind, clinical study to determine the 80-minute water resistant SPF of three sunscreen lip balms. Each participant will evaluate two of the three test products, an SPF standard and no treatment. Study treatments will be randomly assigned to 4 test sites delineated on the skin of the participant's back. The two test products will be applied to their allocated test sites prior to the 80-minute water immersion procedure (four 20-minute water immersion periods, each followed by a 15-minute air-drying period); the SPF standard will be applied to its allocated test site on completion of the final air-drying period. Test sites will be exposed to doses of ultraviolet (UV) radiation and erythemal response evaluated 16-24 hours later. Minimal erythema dose (MED) will be determined for protected and unprotected sites and used to determine the SPF value of each test product.
The study will evaluate the comparative effectiveness of two psychosocial approaches, Cognitive Behavioral Therapy and peer support through the use of Certified Recovery Specialists provided within the context of office-based buprenorphine treatment. Patients will be randomly assigned to receive either (1) standard Medication Management (MM) as typically provided at the site, (2) MM with office-based CBT, (3) MM with CRS, and (4) MM with both CBT and CRS. In MM, patients will be seen by providers at least weekly until stable, and stabilized patients will then be seen by the provider on a monthly basis. If a patient needs a higher level of care, they will be referred to appropriate specialty treatment to ensure their safety. In the CBT study arms, CBT will be provided through 12 individual manualized sessions scheduled to coincide with patients' MM appointments when possible. As outlined by the National Institute on Drug Abuse (NIDA), sessions will cover standard CBT topics and include exercises and homework. Meta-analyses and reviews have concluded that CBT is an effective treatment across a range of SUDs and has helped to enhance treatment retention, improve medication adherence, and address ancillary problems. In the CRS study arms, CRS's will meet with clients following their first OBOT session to assist them in accessing community resources and overcoming treatment barriers, and provide ongoing patient navigation services to promote attendance at OBOT appointments. These appointments will occur either in-person or over the phone and all meetings will be tracked by the CRS. Studies indicate that peer-delivered services for individuals with mental health disorders are effective in engaging "difficult-to-reach" individuals and improving multidimensional outcomes. In the combined CBT/CRS study arm, clients will receive the individual CBT sessions and be assigned to a CRS.
The invention relates to the technical field of the science and technology of dosage forms with controlled release of a drug. The present invention regards a dosage form for the controlled release of a drug present therein comprising a calcium sulphate and/or calcium carbonate, preferably a calcium sulphate dihydrate, or a calcium salt with equivalent physical and chemical activity, a collagen and at least one drug. Said dosage form is advantageously used in a method of controlled release (also referred to as prolonged or delayed, EMA, 2014) endowed with a regulatory mechanism inside the specific composition. In greater detail, the invention relates to a dosage form consisting in a composition that comprises a mixture which comprises or, alternatively, consists of (i) a calcium sulphate and/or a calcium carbonate, preferably a calcium sulphate dihydrate, or a calcium salt with equivalent physical and chemical activity, (ii) a collagen and (iii) at least one drug or an active ingredient for pharmaceutical use. In the context of the present invention, the term drug is understood in the sense of active ingredient for pharmaceutical use. In the dosage form of the present invention, the release of the individual components, for example in a controlled or prolonged or delayed mode, takes place via a process of dissolution or solubilisation, the rate and kinetics of which are regulated by the ratio set between the collagen and the calcium salt present in the composition or in the dosage form. The drug is released thanks to the ratio set, at the time of preparation, between the collagen and the calcium salt. Advantageously, this regulatory mechanism simplifies the preparation, experimental study and industrial production of the dosage forms with controlled release. The present invention has been successfully applied to various drugs, as shown in the description that follows.
Oxaliplatin Injection USP is supplied in clear, glass, single-dose vials with gray elastomeric stoppers and aluminum flip-off seals containing 50 mg or 100 mg of oxaliplatin as a clear, colorless, sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL. 

NDC 60505-6287-2: 50 mg/10 mL single-dose vial with flip-off seal individually packaged in a carton.

NDC 60505-6287-4: 100 mg/20 mL single-dose vial with flip-off seal individually packaged in a carton.

Store at 25°C (77°F); excursions permitted between 15 to 30°C (59 to 86°F) [See USP Controlled Room Temperature]. Do not freeze and protect from light (keep in original outer carton). Discard unused portion.

Oxaliplatin Injection USP is a cytotoxic drug. Follow applicable special handling and disposal procedures.1 The use of gloves is recommended. If a solution of Oxaliplatin Injection USP contacts the skin, wash the skin immediately and thoroughly with soap and water. If Oxaliplatin Injection USP contacts the mucous membranes, flush thoroughly with water.
It has been reported in a number of studies that methods utilizing laser are practical, easy, portable, and inexpensive in clinical use, a standardized and branded laser apparatus and system have not been identified. This has caused problems about whether the laser equipment used in the literature is valid and reliable in the evaluation of cervical proprioception (CP). Besides, the head repositioning accuracy (HRA) test, which was designed before for CP assessment and standardized with trigonometric equations, carries out measurements in the frontal plane. In addition, cervical rotation in the atlanto-axial joint occurs in the horizontal plane. Therefore, the investigators presume that evaluating the biomechanical motion occurring in the horizontal plane and transferring it directly to the horizontal plane will be more practical and reliable for practitioners.

The subjects' HRA values were measured through AOS ProPoint® device in the horizontal and frontal platforms and also through the CROM device. Each measurement was repeated bilaterally three times, and they were averaged. To validate the measurement method, a comparison between the CROM device used as the gold standard and the measurement values was made. Test-retest and inter-rater reliability scores were calculated to evaluate the reliability of the horizontal measurement method.
PURPOSE: The implementation of enhanced recovery after surgery programs (ERPs) has significantly improved outcomes within various surgical specialties. However, the suitability of ERPs in trauma surgery remains unclear. This study aimed to (1) design and implement an ERP for trauma laparotomy patients; (2) assess its safety, feasibility, and efficacy; and (3) compare the outcomes of the proposed ERP with conventional practices.
METHODS: This case-matched study prospectively enrolled hemodynamically stable patients undergoing emergency laparotomy after penetrating trauma. Patients receiving the proposed ERP were compared to historical controls who had received conventional treatment from two to eight years prior to protocol implementation. Cases were matched for age, sex, injury mechanism, extra-abdominal injuries, and trauma scores. Assessment of intervention effects were modelled using regression analysis for outcome measures, including length of hospital stay (LOS), postoperative complications, and functional recovery parameters.
RESULTS: Thirty-six consecutive patients were enrolled in the proposed ERP and matched to their 36 historical counterparts, totaling 72 participants. A statistically significant decrease in LOS, representing a 39% improvement in average LOS was observed. There was no difference in the incidence of postoperative complications. Opioid consumption was considerably lower in the ERP group (p < 0.010). Time to resumption of oral liquid and solid intake, as well as to the removal of nasogastric tubes, urinary catheters, and abdominal drains was significantly earlier among ERP patients (p < 0.001).
CONCLUSION: The implementation of a standardized ERP for the perioperative care of penetrating abdominal trauma patients yielded a significant reduction in LOS without increasing postoperative complications. These findings demonstrate that ERPs principles can be safely applied to selected trauma patients.
The training sessions were based on the Dialectical Behavior Therapy Skills (Linehan, 2015). Each group received eight 90-min sessions of the emotion regulation training (one session per week) carried out by qualified clinical psychologist. The training includes group gathering, homework and telephone consultation as needed.
Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 gram (10 mL) four times per day. Sucralfate Oral Suspension should be administered on an empty stomach.

Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Sucralfate Oral Suspension.

While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.

Elderly. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS Geriatric Use).

Call your doctor for medical advice about side effects. You may report side effects to VistaPharm, LLC, at 1-888-655-1505 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Extract of Ginkgo biloba is prepared by extracting Ginkgo biloba leaves at 40-100[deg]C with e.g. aqueous acetone, separating solvent, diluting concentrated solution with water, cooling, removing resulting precipitate, extracting solution with methyl ethyl ketone and/or acetone, concentrating, diluting, filtering, adding lead salt solution, extracting aqueous alcoholic solution with heptane to remove alkylphenol compounds, drying, adding ethanol, filtering and drying. Preparation of an extract from Ginkgo biloba having a reduced polycyclic aromatic hydrocarbons content, involves: (a) extracting fresh or dried green leaves of Ginkgo biloba (drug) at 40-100[deg]C using aqueous acetone, an aqueous 1-3C alkanol or anhydrous methanol; (b) separating the organic solvent from the extract to a maximum content of 2 wt.%, where water may be added during the final distillation steps; (c) diluting the remaining concentrated aqueous solution with water to a solid content of 5-25 wt.%, cooling under agitation to below 6[deg]C, allowing to stand for at least 1 hour at this temperature and removing the resulting precipitate comprising lipophilic components which are not completely soluble in water; (d) adding ammonium sulfate to the remaining aqueous solution and extracting the solution formed with methyl ethyl ketone and/or acetone; (e) concentrating the obtained extract to a solid content of 50-70 wt.% and diluting the obtained concentrate with water and ethanol such that a solution containing water (50 wt.%) and ethanol (50 wt.%) at a solids content of 10 wt.% is obtained, filtration is carried out and filtrate is further processed in step (f); (f) adding an aqueous solution of a lead salt to the solution thus obtained until a change in color from brown to amber occurs, and removing the precipitate formed, or using a polyamide instead of the lead salt; (g) extracting the remaining aqueous alcoholic solution with heptane in order to further remove the alkylphenol compounds; (h) concentrating the remaining aqueous alcoholic solution under reduced pressure to an ethanol content of 5 wt.% and added with ammonium sulfate (20 wt.%); (i) extracting the solution obtained with a mixture of methyl ethyl ketone and ethanol in a ratio of 8:2-5:5 (weight/weight); (j) drying the resulting organic phase with ammonium sulfate (=20 wt.%) and concentrating to solid content of 50-70 wt.%, added with ethanol such that an ethanol content of at least 80 wt.% is obtained, maintained for at least 2 h at =12[deg]C and filtered; and (k) concentrating the resulting filtrate under reduced pressure at a maximum temperature of 60-80[deg]C and dried to obtain a dry extract having a water content of less than 5 wt.%. Independent claims are included for the following: (1) an extract obtained from Ginkgo biloba having a reduced polycyclic aromatic hydrocarbons content by the method; and (2) a medicament, food product or other preparation comprising the extract. ACTIVITY : Nootropic; Cerebroprotective; Cardiovascular-Gen. No biological data given. MECHANISM OF ACTION : None given.
The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A "mini program" (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided.
The hepatocellular carcinoma (HCC) features a remarkable epidemiological burden, ranking as the third most lethal cancer worldwide. As the HCC-related molecular and cellular complexity unfolds as the disease progresses, the use of a myriad of in vitro models available is mandatory in translational preclinical research setups. In this review paper, we will compile cutting-edge information on the in vitro bioassays for HCC research, (A) emphasizing their morphological and molecular parallels with human HCC; (B) delineating the advantages and limitations of their application; and (C) offering perspectives on their prospective applications. While bidimensional (2D) (co) culture setups provide a rapid low-cost strategy for metabolism and drug screening investigations, tridimensional (3D) (co) culture bioassays - including patient-derived protocols as organoids and precision cut slices - surpass some of the 2D strategies limitations, mimicking the complex microarchitecture and cellular and non-cellular microenvironment observed in human HCC. 3D models have become invaluable tools to unveil HCC pathophysiology and targeted therapy. In both setups, the recapitulation of HCC in different etiologies/backgrounds (i.e., viral, fibrosis, and fatty liver) may be considered as a fundamental guide for obtaining translational findings. Therefore, a "multimodel" approach - encompassing the advantages of different in vitro bioassays - is encouraged to circumvent "model-biased" outcomes in preclinical HCC research.
The invention discloses a formula of a Hui-nationality Chinese herbal Chinaroot Greenbier Rhizome esophagus cancer inhibiting tablet and a preparation method thereof. The medicine is a green high-tech Chinese herbal medicine for treating esophagus cancer. The preparation method comprises the following steps: mixing Chinese herbal medicines such as Chinaroot Greenbier Rhizome, rhizoma curcumae, Stephania tetrandra, salammonite, etc. according to a certain ratio, adding water and decocting, extracting, concentrating and tabletting to obtain a traditional Chinese medicine tablet, which is used for mainly treating esophagus cancer as well as treating digestive cancers such as pharyngolaryngeal cancer, gastric cancer, colorectal cancer, etc. The invention has the characteristics of moderate medicinal odour and dosage. The selected medicines are proved through pharmacology experiments of modern medicine to be capable of treating cancers. The medicine can fundamentally improve body functions at low cost and prevent cell cancerization so as to recover body health.